Cefotiam therapy of lower respiratory tract infections.

AUTOR(ES)

Polis, M A

RESUMO

Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.

Documentos Relacionados

• Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.
• Therapy of lower respiratory tract infections with moxalactam.
• Nonvalue of sputum culture in the management of lower respiratory tract infections.
• Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections.
• Pharmacokinetics of cefepime in patients with respiratory tract infections.